GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Santen Pharmaceutical Co Ltd (OTCPK:SNPHY) » Definitions » Scaled Net Operating Assets

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Scaled Net Operating Assets : 0.52 (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Santen Pharmaceutical Co Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Santen Pharmaceutical Co's operating assets for the quarter that ended in Dec. 2023 was $2,392 Mil. Santen Pharmaceutical Co's operating liabilities for the quarter that ended in Dec. 2023 was $902 Mil. Santen Pharmaceutical Co's Total Assets for the quarter that ended in Sep. 2023 was $2,888 Mil. Therefore, Santen Pharmaceutical Co's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was 0.52.


Santen Pharmaceutical Co Scaled Net Operating Assets Historical Data

The historical data trend for Santen Pharmaceutical Co's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santen Pharmaceutical Co Scaled Net Operating Assets Chart

Santen Pharmaceutical Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.54 0.56 0.60 0.57 0.45

Santen Pharmaceutical Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.59 0.56 0.57 0.55 0.52

Competitive Comparison of Santen Pharmaceutical Co's Scaled Net Operating Assets

For the Drug Manufacturers - General subindustry, Santen Pharmaceutical Co's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Santen Pharmaceutical Co's Scaled Net Operating Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Santen Pharmaceutical Co's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Santen Pharmaceutical Co's Scaled Net Operating Assets falls into.



Santen Pharmaceutical Co Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Santen Pharmaceutical Co's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Mar. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Mar. 2023 )
=(Operating Assets (A: Mar. 2023 )-Operating Liabilities (A: Mar. 2023 ))/Total Assets (A: Mar. 2022 )
=(2712.033-956.74)/3879.12
=0.45

where

Operating Assets(A: Mar. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=3151.021 - 438.988
=2712.033

Operating Liabilities(A: Mar. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=956.74 - 0 - 0
=956.74

Santen Pharmaceutical Co's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2023 )
=(Operating Assets (Q: Dec. 2023 )-Operating Liabilities (Q: Dec. 2023 ))/Total Assets (Q: Sep. 2023 )
=(2392.405-901.755)/2888.052
=0.52

where

Operating Assets(Q: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=2971.354 - 578.949
=2392.405

Operating Liabilities(Q: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=901.755 - 0 - 0
=901.755

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Santen Pharmaceutical Co Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Santen Pharmaceutical Co's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Santen Pharmaceutical Co (Santen Pharmaceutical Co) Business Description

Traded in Other Exchanges
Address
Grand Front Osaka Tower A, 4-20 Ofuka-cho, Kita-ku, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company reports two primary operating segments: prescription ophthalmic pharmaceuticals and other. The pharmaceuticals segment includes over-the-counter pharmaceuticals, while the other segment includes medical devices. The vast majority of Santen's revenue is derived from its prescription ophthalmic pharmaceuticals segment, which manufactures and distributes prescription and OTC pharmaceuticals. Most of Santen's sales are generated in Japan, followed by other Asian countries.

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Headlines

From GuruFocus

Matthews Japan Fund 1st-Quarter Commentary

By Sydnee Gatewood Sydnee Gatewood 04-23-2020

Matthews Japan Fund Comments on Santen Pharmaceutical

By Sydnee Gatewood Sydnee Gatewood 04-23-2020